rosiglitazone + quinine sulfate

This is an oral combination regimen consisting of **rosiglitazone**, a thiazolidinedione-class antidiabetic agent, and **quinine sulfate**, traditionally an antimalarial drug. In this context, quinine sulfate functions as a cytochrome P450 2C8 (CYP2C8) inhibitor, used experimentally to investigate its impact on the pharmacokinetics of rosiglitazone, which is metabolized via the same enzyme. Rosiglitazone acts as an agonist at the peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity in peripheral tissues. This combination is not an approved or marketed fixed-dose pharmaceutical product but rather has been studied in clinical pharmacology settings for drug-drug interaction research, particularly for the effect of CYP2C8 inhibition on rosiglitazone exposure[1][4].